1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
66A19FC57A3039D3A00258BF5004D57E6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/utilizing-advanced-analytics-ai-ml-for-competitive-intelligence-excellence
18
19
20172.70.100.144
21
22
23116639.0ncwlf7ax.asia
24/bestp/domrep.nsf
25BMR




» Products & Services » » Competitive and Business Intelligence » Structure and Alignment

Utilizing Advanced Analytics and AI/ML for Competitive Intelligence Excellence

ID: PSM-394


Features:

4 Info Graphics

26 Data Graphics

370+ Metrics

16 Narratives


Pages: 38


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Competitive Intelligence (CI) functions are rapidly evolving as organizations seek to enhance their data gathering and decision-making processes through the integration of advanced analytics and artificial intelligence (AI/ML) tools. Despite significant potential, the adoption and operationalization of these capabilities remains uneven, often constrained by resource limitations and organizational alignment challenges.

This updated report from Best Practices, LLC examines how CI teams navigate these barriers to strengthen their strategic value and operational efficiency. By exploring the strengths and weaknesses of various CI structural models, this research identifies hallmarks of analytics and AI/ML maturity in CI functions, benchmarks key performance metrics, and evaluates study types best suited for advanced analytics or AI/ML supplementation.

This updated version expands on the integration of advanced analytics and AI/ML in CI, offering fresh insights into a period of rapid transition and growth for innovative biopharma organizations.

Industries Profiled:
Pharmaceutical; Health Care; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Laboratories; Clinical Research


Companies Profiled:
AbbVie; Abbott; Alkermes; Bayer; BIAL; Biogen; Biotest AG; BlueRock Therapeutics; CooperSurgical; Grifols; Jazz Pharmaceuticals; Johnson & Johnson; Paratek Pharmaceuticals; Pierre Fabre; Sanofi; SCIEX; Scilex Pharmaceuticals; Inc.; Servier; Syndax Pharmaceuticals; Taiho Oncology; Vir Biotechnology; Ventus Therapeutics

Study Snapshot

Best Practices, LLC engaged 24 Competitive Intelligence and AI experts from 22 leading biopharma organizations in this latest benchmarking research. This study also features a comparative analysis of previous benchmarking studies, uncovering evolutionary insights to drive the future of the CI function.

Key topics covered in this report include:

  • Evolving CI Group Structures and Key Maturity Drivers
  • Budget Alignment and Coordination for CI Initiatives
  • Leveraging CI Centers of Excellence (CoE)
  • Building Effective CI Teams: Staff Size, Expertise, and Skills
  • CI Activity Priorities and Stakeholders
  • Unlocking the Potential of Advanced Analytics and AI/ML in Competitive Intelligence

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Structural Focus: Organizations are moving away from informal and regionally decentralized CI structures toward hybrid models, with most expecting this shift within the next 24 months.
  • Role of Advanced Analytics and AI/ML: Analytics in CI are primarily used to inform commercial and business strategies, but adoption of AI/ML remains nascent, with most organizations in early implementation stages and many systems still requiring human intervention.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Benchmark ClassPg. 3
II.
Key Findings and TakeawaysPg. 4
III.
CI Models, Reporting, Performance, and Structure TrendsPg. 8
IV.
CI Staffing, Activities, and Critical Training NeedsPg. 19
V.
AI Snapshots: The Accelerating Use of AI Tools Transforming CI OrganizationsPg. 31
VI.
Participant DemographicsPg. 35
VII.
About Best Practices, LLCPg. 38

    List of Charts & Exhibits

    I. Benchmark Class and Key Takeaways

    • Benchmark study partners
    • Business issue, key insights, and recommendations
    • Shift in CI structures and operating model (2001–2024): A longitudinal view
    • Analytical expertise of benchmark study partners

    II. CI Models, Reporting, Performance, and Structure Trends

    • Current operating model for the CI function
    • Planned operating model for the CI function within the next 24 months
    • Comparing the current and future CI operating models
    • Reasons for evolution in CI operating models
    • Hallmarks of maturity of the Competitive Intelligence function
    • Goals for utilizing advanced tools such as AI and machine learning in CI
    • Budget coordination of the Competitive Intelligence function
    • Mapping the Center of Excellence (CoE) in the organizational framework

    III. CI Staffing, Activities, and Critical Training Needs

    • Total FTEs in the CI function for the most recent fiscal year
    • Primary stakeholders of the Competitive Intelligence function
    • Strategic practices that enhance stakeholder value in Competitive Intelligence
    • Internal branding campaigns to reshape the perception of the CI function
    • Key objectives of the CI internal branding program and their importance
    • Core activities undertaken by the CI function
    • Prioritizing CI activities for maximum efficiency
    • Comparison of conducted activities and their importance rankings
    • Analytic methodologies used by the CI group and their operational purposes
    • Essential soft skills and professional experiences for CI Professionals

    IV. AI Snapshots: The Accelerating Use of AI Tools Transforming CI Organizations

    • AI applications and effectiveness in Competitive Intelligence
    • Challenges and gaps in AI implementation for CI
    • Voices from the field: AI impact and experiences in Competitive Intelligence

    V. Participant Demographics

    • Geographic span of responsibility of the CI functions represented by benchmark partners
    • Primary therapeutic areas supported by benchmark CI functions